Crispr Therapeutics initiated at Wells Fargo

Crispr Therapeutics initiated with an Outperform at Wells Fargo. Wells Fargo analyst Jim Birchenough started Crispr Therapeutics with an Outperform rating and $65 price target. The analyst cited the company’s “highly leverageable” gene editing platform, “substantially de-risked” lead program in ex-vivo gene editing for beta thalassemia and sickle cell disease, a broad pipeline of both ex vivo and in vivo gene-editing opportunities, and strong collaborations balancing wholly owned programs to optimize future value creation.
https://thefly.com/landingPageNews.php?id=2802107